Literature DB >> 19491013

Lipophilic pyrazinoic acid amide and ester prodrugs stability, activation and activity against M. tuberculosis.

Marta Filipa Simões1, Emília Valente, M José Rodríguez Gómez, Elsa Anes, Luís Constantino.   

Abstract

Pyrazinamide (PZA) is active against M. tuberculosis and is a first line agent for the treatment of human tuberculosis. PZA is itself a prodrug that requires activation by a pyrazinamidase to form its active metabolite pyrazinoic acid (POA). Since the specificity of cleavage is dependent on a single bacterial enzyme, resistance to PZA is often found in tuberculosis patients. Esters of POA have been proposed in the past as alternatives to PZA however the most promising compounds were rapidly degraded in the presence of serum. In order to obtain compounds that could survive during the transport phase, we synthesized lipophilic ester and amide POA derivatives, studied their activity against M. tuberculosis, their stability in plasma and rat liver homogenate and also their activation by a mycobacterial homogenate. The new lipophilic ester prodrugs were found to be active in concentrations 10-fold lower than those needed for PZA to kill sensitive M. tuberculosis and also have a suitable stability in the presence of plasma. Amides of POA although more stable in plasma have lower activity. The reason can probably be found in the rate of activation of both types of prodrugs; while esters are easily activated by mycobacterial esterases, amides are resistant to activation and are not transformed into POA at a suitable rate.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19491013     DOI: 10.1016/j.ejps.2009.02.012

Source DB:  PubMed          Journal:  Eur J Pharm Sci        ISSN: 0928-0987            Impact factor:   4.384


  12 in total

1.  Inhaled Pyrazinoic Acid Esters for the Treatment of Tuberculosis.

Authors:  E F Young; E Perkowski; S Malik; J D Hayden; P G Durham; L Zhong; J T Welch; Miriam S Braunstein; Anthony J Hickey
Journal:  Pharm Res       Date:  2016-06-28       Impact factor: 4.200

2.  Esters of Pyrazinoic Acid Are Active against Pyrazinamide-Resistant Strains of Mycobacterium tuberculosis and Other Naturally Resistant Mycobacteria In Vitro and Ex Vivo within Macrophages.

Authors:  David Pires; Emília Valente; Marta Filipa Simões; Nuno Carmo; Bernard Testa; Luís Constantino; Elsa Anes
Journal:  Antimicrob Agents Chemother       Date:  2015-10-05       Impact factor: 5.191

3.  Pyrazolo[3,4-d]pyrimidine Prodrugs: Strategic Optimization of the Aqueous Solubility of Dual Src/Abl Inhibitors.

Authors:  Giulia Vignaroli; Claudio Zamperini; Elena Dreassi; Marco Radi; Adriano Angelucci; Patrizia Sanità; Emmanuele Crespan; Miroslava Kissova; Giovanni Maga; Silvia Schenone; Francesca Musumeci; Maurizio Botta
Journal:  ACS Med Chem Lett       Date:  2013-05-20       Impact factor: 4.345

4.  High Systemic Exposure of Pyrazinoic Acid Has Limited Antituberculosis Activity in Murine and Rabbit Models of Tuberculosis.

Authors:  Jean-Philippe Lanoix; Rokeya Tasneen; Paul O'Brien; Jansy Sarathy; Hassan Safi; Michael Pinn; David Alland; Véronique Dartois; Eric Nuermberger
Journal:  Antimicrob Agents Chemother       Date:  2016-06-20       Impact factor: 5.191

5.  Ester-prodrugs of ethambutol control its antibacterial activity and provide rapid screening for mycobacterial hydrolase activity.

Authors:  Erik M Larsen; Dominique C Stephens; Nathan H Clarke; R Jeremy Johnson
Journal:  Bioorg Med Chem Lett       Date:  2017-08-30       Impact factor: 2.823

Review 6.  Microbial esterases and ester prodrugs: An unlikely marriage for combating antibiotic resistance.

Authors:  Erik M Larsen; R Jeremy Johnson
Journal:  Drug Dev Res       Date:  2018-10-10       Impact factor: 4.360

7.  Docking studies on novel analogues of 8 methoxy fluoroquinolones against GyrA mutants of Mycobacterium tuberculosis.

Authors:  R S Anand; Sulochana Somasundaram; Mukesh Doble; C N Paramasivan
Journal:  BMC Struct Biol       Date:  2011-12-12

8.  A new painkiller nanomedicine to bypass the blood-brain barrier and the use of morphine.

Authors:  Jiao Feng; Sinda Lepetre-Mouelhi; Anne Gautier; Simona Mura; Catherine Cailleau; François Coudore; Michel Hamon; Patrick Couvreur
Journal:  Sci Adv       Date:  2019-02-13       Impact factor: 14.136

9.  Synthesis and evaluation of a pyrazinoic acid prodrug in Mycobacterium tuberculosis.

Authors:  João Paulo-Dos Santos Fernandes; Fernando Rogerio Pavan; Clarice Queico Fujimura Leite; Veni Maria Andres Felli
Journal:  Saudi Pharm J       Date:  2013-12-25       Impact factor: 4.330

10.  Bactericidal activity of PA-824 against Mycobacterium tuberculosis under anaerobic conditions and computational analysis of its novel analogues against mutant Ddn receptor.

Authors:  Sulochana Somasundaram; Ramaian Santhaseela Anand; Perumal Venkatesan; Chinnambedu N Paramasivan
Journal:  BMC Microbiol       Date:  2013-10-01       Impact factor: 3.605

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.